Navigation Links
Medco Issues $1.5 Billion of Senior Notes

FRANKLIN LAKES, N.J., March 13 /PRNewswire-FirstCall/ -- Medco Health Solutions, Inc. (NYSE: MHS) announced today that it has agreed to sell $300 million aggregate principal amount of 6-1/8 percent senior notes due March 15, 2013 and $1.2 billion aggregate principal amount of 7-1/8 percent senior notes due March 15, 2018 in an underwritten public offering. Citi, J.P. Morgan Securities Inc., Banc of America Securities LLC and Barclays Capital Inc. are acting as representatives of the several underwriters.

Medco intends to use the net proceeds from the offering to repay borrowings under its senior unsecured revolving credit facility used to fund the acquisition of PolyMedica Corporation in October 2007. The offering is expected to close on March 18, 2008. The prospectus supplement and accompanying prospectus related to the offering of the notes may be obtained by contacting:

Citigroup Global Markets Inc.

Brooklyn Army Terminal,

140 58th Street, 8th Floor,

Brooklyn, NY 11220

Tel: (877) 858 5407

J.P. Morgan Securities Inc.

270 Park Avenue, 8th Floor,

New York, New York, 10017

Tel: (212) 834-4533

Banc of America Securities LLC

Capital Markets Operations

100 West 33rd Street, 3rd Floor

New York, NY 10001

Tel: (800) 294-1322

Barclays Capital Inc.

200 Park Avenue

New York, NY 10166

Attention: Fixed Income Syndicate

Tel: (888) 227-2275

Electronic copies of the prospectus supplement and accompanying prospectus are also available on the Securities and Exchange Commission Web site at

This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

About Medco

Medco Health Solutions, Inc. (NYSE: MHS) is the nation's leading pharmacy benefit manager based on its 2007 total net revenues of more than $44 billion. Medco's prescription drug benefit programs, covering one in five Americans, are designed to drive down the cost of pharmacy health care for private and public employers, health plans, labor unions and government agencies of all sizes, and for individuals served by the Medicare Part D Prescription Drug Program. Medco, the world's most advanced pharmacy(TM), is positioned to serve the unique needs of patients with chronic and complex conditions through its Medco Therapeutic Resource Centers; its diabetes pharmacy care practice, Liberty Medical; and its specialty pharmacy operation, Accredo Health Group, Inc. Medco is the highest-ranked independent pharmacy benefit manager on the 2007 Fortune 500 list. On the Net:

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that may cause results to differ materially from those set forth in the statements. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. We undertake no obligation to publicly update any forward- looking statement, whether as a result of new information, future events or otherwise. Forward-looking statements are not historical facts, but rather are based on current expectations, estimates, assumptions and projections about the business and future financial results of the pharmacy benefit management ("PBM") and specialty pharmacy industries, and other legal, regulatory and economic developments. We use words such as "anticipates," "believes," "plans," "expects," "projects," "future," "intends," "may," "will," "should," "could," "estimates," "predicts," "potential," "continue," "guidance" and similar expressions to identify these forward-looking statements. Medco's actual results could differ materially from the results contemplated by these forward-looking statements due to a number of factors.

SOURCE Medco Health Solutions, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Addressing the Pharmacist Shortage: Medco Labor Coalition(TM) Launches National Scholarship Program to Support the Development of the Next Generation of Pharmacists
2. Medco Chooses AllPoints at Anson in Whitestown, Indiana as Site for the Worlds Largest, Most-Advanced Automated Pharmacy
3. Medco to Webcast Annual Analyst Day Conference
4. Medco Announces Agreement to Acquire Diabetes Care Leader PolyMedica in Transaction Valued at $1.5 Billion
5. Issues MarketStats on CVBT, BSX, MDT, CXM and DNA
6. Solstice Neurosciences, Inc. Issues Corporate Response to FDA Early Communication
7. Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics
8. Baxter Issues Urgent Nationwide Voluntary Recall of Heparin 1,000 Units/mL 10 and 30mL Multi-Dose Vials
9. FDA Issues Approvable Letter for LUVOX(R) CR (Fluvoxamine Maleate) Extended-Release Capsules for the Treatment of Social Anxiety Disorder (SAD) and Obsessive Compulsive Disorder (OCD)
10. Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants
11. CCPM Issues Statement on FDAs GIVE Initiative
Post Your Comments:
(Date:11/24/2015)... India , November 24, 2015 ... a new market research report "Oligonucleotide Synthesis Market by ... Application (PCR, Gene Synthesis, Diagnostic, DNA, RNAi), End-User (Research, ... 2020", published by MarketsandMarkets, the market is expected to ... Million in 2015, at a CAGR of 10.1% during ...
(Date:11/24/2015)... ALBANY, New York , November 24, 2015 /PRNewswire/ ... According to a recent market research report released by ... is projected to expand at a CAGR of 17.5% ... titled "Non-invasive Prenatal Testing Market - Global Industry Analysis, ... 2022", estimates the global non-invasive prenatal testing market to ...
(Date:11/24/2015)... ... November 24, 2015 , ... In harsh ... Insertion points for in-line sensors can represent a weak spot where leaking process ... series of retractable sensor housings , which are designed to tolerate extreme process ...
(Date:11/24/2015)... 2015 Capricor Therapeutics, Inc. (NASDAQ: ... discovery, development and commercialization of first-in-class therapeutics, today announced ... is scheduled to present at the 2015 Piper Jaffray ... EST, at The Lotte New York Palace Hotel in ... . --> . ...
Breaking Biology Technology:
(Date:11/17/2015)... Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and ... of broadly enabling, pressure cycling technology ("PCT")-based sample preparation ... it has received gross proceeds of $745,000 from an ... "Offering"), increasing the total amount raised to date in ... are expected in the near future. ...
(Date:11/12/2015)... Nov. 12, 2015  A golden retriever that stayed ... dystrophy (DMD) has provided a new lead for treating ... the Broad Institute of MIT and Harvard and the ... . Cell, pinpoints a protective ... the disease,s effects. The Boston Children,s lab of ...
(Date:11/12/2015)... --  Growing need for low-cost, easy to use, ... the way for use of biochemical sensors for ... clinical, agricultural, environmental, food and defense applications. Presently, ... applications, however, their adoption is increasing in agricultural, ... on improving product quality and growing need to ...
Breaking Biology News(10 mins):